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To the Editor:
We thank Knobloch et al for their comments about the
development and validation of the URAM scale for Du-
puytren’s disease. The URAM scale is indeed a tool to
assess patient-reported functional outcome in Dupuytren’s
disease and we agree that assessing disability is of key
importance in Dupuytren’s disease. However, we would
like to respond to a few points made by Knobloch et al. We
emphasize that the validation of a scale for a specific
condition has to be done in the disease being considered
and not another disease. Specificity here is a question of
what disease from which the scale has been developed and
in which it has been validated, and of functional limitation
due to the considered condition; it is not only a question of
side (right hand or left hand). Validation means studying
the reliability, the construct validity, and the responsive-
ness as has been done for the URAM scale. To our knowl-
edge, neither the DASH nor the MHQ have been validated
in such a way for Dupuytren’s disease. Our opinion is that
nonvalidated scales should not be recommended and used
to assess disability in Dupuytren’s disease.
Nonetheless, we are grateful to Knobloch et al for their
German translation of the URAM scale. We compliment
them for using the French language version and translating
it into the German language version using sound method-
ology. We encourage using the URAM scale in patients
with Dupuytren’s disease, including German patients. In-
deed, assessment of the disease should not be limited to
the flexion contracture. A patient’s subjective perception
of their own difficulties in daily living is pertinent in
current practice and recommended in clinical trials (1,2).
The URAM scale is the only scale developed and validated
to assess disability in Dupuytren’s disease. Therefore, the
URAM scale should be part of the assessment of Dupuytren’s
disease in current practice and in future clinical trials.
Finally, we agree with Knobloch et al that the recurrence
rate is also of key importance for assessing effectiveness of
treatments in Dupuytren’s disease and that a consensus def-
inition of recurrence is needed. Several definitions have
previously been proposed and used, including reappearance
of cords, nodules, or contracture requiring further operation
with followup of a few months to several years (3). A con-
sensus definition of recurrence should therefore include the
criteria for recurrence and the time of its assessment.
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Interreader agreement in determining
monosodium urate deposition using
musculoskeletal ultrasound: comment on
the article by Howard et al
To the Editor:
We read with interest the article by Howard et al in a
recent issue of Arthritis Care & Research on the reproduc-
ibility of musculoskeletal ultrasound (US) for detecting
monosodium urate (MSU) deposition (1). In this article, the
authors found an almost perfect agreement between 2 readers
for the US identification of intraarticular tophi and the dou-
ble contour sign of the hyaline cartilage in the first metatar-
sophalangeal and knee joints of patients with gout, patients
with asymptomatic hyperuricemia, and healthy controls.
In a previous study by Filippucci et al (2), the interob-
server exact agreement for the double contour sign of the
hyaline cartilage in the knee was 92.7%, while the un-
weighted kappa value was 0.68, which are much lower
than the values reported by Howard et al. We would like to
raise some issues that could have influenced these results
and, in our opinion, need to be addressed.
First, the US examinations were performed by 1 sonog-
rapher and the reproducibility was tested on the ability to
recognize US findings in static images. Postacquisition
reading of the images is likely to perform better than in-
terpretation during real-time acquisition. The scanning
technique may affect reading in several ways, leading to
easy recognition of US findings when properly carried out,
or conversely leading to misinterpretation due to subopti-
mal adjustment of the setting parameters and/or the probe
positioning. Another issue that needs to be addressed is
whether the sonographer was blinded to the patients’ sta-
tus (gout/hyperuricemia/healthy) or not.
Second, the exclusion of patients with arthritis from the
control group facilitates the reader’s work. Intraarticular
tophi, as described in the study, are not always easy to
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distinguish from synovitis, which could have similar ul-
trasonographic characteristics (3).
Third, another aspect that could have influenced the
agreement is the US background shared by the 2 readers.
Therefore, the following data may be of interest: years of
US experience for each reader, US training shared by the 2
readers, and number of US images showing MSU deposi-
tion and/or the number of patients with gout examined
together before the beginning of the study.
Studies on the use of US in crystal deposition diseases
are of great interest and represent relevant contributions to
the evidence of US validity in the assessment of findings
indicative of MSU deposition. Since we believe that US is
an operator-dependent technique par excellence, all of the
steps from image acquisition to image interpretation need
to be investigated for assessing reliability. Finally, we
agree with the authors that US diagnosis of microcrystal-
line arthritis represents a challenge for all sonographers
mainly because of the lack of a noninvasive and univer-
sally accepted gold standard imaging tool.
Georgios Filippou, MD
Bruno Frediani, MD
University of Siena
Siena, Italy
Andrea Delle Sedie, MD
Stefano Bombardieri, MD
University of Pisa
Pisa, Italy
Emilio Filippucci, MD
Walter Grassi, MD
Universita` Politecnica delle Marche
Ancona, Italy
Annamaria Iagnocco, MD
Guido Valesini, MD
Sapienza Universita` di Roma
Rome, Italy
1. Howard RG, Pillinger MH, Gyftopoulos S, Thiele RG, Swear-
ingen CJ, Samuels J. Reproducibility of musculoskeletal ultra-
sound for determining monosodium urate deposition: concor-
dance between readers. Arthritis Care Res (Hoboken) 2011;63:
1456–62.
2. Filippucci E, Gutierrez M, Georgescu D, Salaffi F, Grassi W.
Hyaline cartilage involvement in patients with gout and cal-
cium pyrophospahate deposition disease: an ultrasound study.
Osteoarthritis Cartilage 2009;17:178–81.
3. Wakefield RJ, Balint P, Szkudlarek M, Filippucci E, Backhaus
M, D’Agostino MA, et al. Musculoskeletal ultrasound includ-
ing definitions for ultrasonographic pathology. J Rheumatol
2005;32:2485–7.
DOI 10.1002/acr.21577
Reply
To the Editor:
We thank Filippou and colleagues for their comments.
We agree that the level of concordance we achieved in our
study was strikingly high, and that the reasons for this
might provide insight into how best to approach the use of
musculoskeletal US for the assessment of gout.
The authors correctly note that our image interpretations
were performed on static images and not at the time of
acquisition. Separating the activities of scanning and im-
age interpretation may have a beneficial effect on the abil-
ity of the reader to apply an objective protocol to interpre-
tation. We agree that standardizing and evaluating the
interreader and intrareader consistency of image acquisi-
tion are important, but we also believe these would be
better served by a separate study. Moreover, the fact that
all images were acquired by a single ultrasonographer
using uniform patient and transducer positioning likely
resulted in consistent views and image quality that al-
lowed for a more homogenous interpretation of images.
Our investigators scored all of the images without any
knowledge of the corresponding patients’ crystalline sta-
tus (gout/hyperuricemia/healthy) by assigning each pa-
tient a number and shuffling the order of images before
evaluation. While the ultrasonographer in our study was
not blinded to the diagnosis, the standardized positioning
of the patients and the probe likely was sufficient in pre-
venting bias in image acquisition that could have altered
the results of the study.
The authors also correctly note that our exclusion of
patients with other forms of arthritis from the control
group may have made it easier for the readers to identify
gout, since the task at hand was largely one of determining
gout versus no gout (or really, crystal deposition versus no
deposition). As this suggests, US may be more useful in
gout assessment when the clinical judgment has already
been reduced to a simple yes/no determination, rather
than asking the ultrasonographer/reader to identify an un-
known diagnosis based strictly on clinical appearance.
Such an interpretation essentially proves the importance
of understanding pretest probability, and in this regard US
may be no different than any other modality. One lesson
from our study may therefore be applying clinical infor-
mation to the fullest extent possible in order to increase
the power of the US study by narrowing the scope of the
question. Conversely, our assessments in this study were
related only to urate deposition, not to the presence of
synovitis or other features of gout that may readily be
found in other diseases. In this regard, the main confound-
ing diagnosis would have been chondrocalcinosis, which
also presents as linear hyperechoic (bright) signals along
(but below the surface of) the cartilage. Patients with
known chondrocalcinosis were excluded from our study;
nevertheless, chondrocalcinosis was detected inciden-
tally, and by both readers, with no confusion as to its
distinction from gout.
Finally, Filippou et al inquire about the background
training of our US readers and suggest that readers with
common training and/or experience may be more likely to
produce concordant readings; we agree with this sugges-
tion completely. In our study, the 2 readers had both
similarities and differences in their skills and experience.
One reader had 4 years of experience with musculoskeletal
US and has served as an instructor at the American College
of Rheumatology biannual US courses designed specifi-
cally for rheumatologists. The other reader had 1 year of
US experience, but spent time with an expert who has
published studies on US in crystal deposition disease in
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